CAAs increase the release of IL-6 to expand the cancer stem cell population by activating an IL-6 inflammatory loop, which results in anti-trastuzumab effects in HER2+ BC patients that is overcome by an IL-6 receptor antibody [147]. This evidence concerns the gene ERBB2 and breast cancer.